Oxford Airways Study
Research type
Research Study
Full title
An observational study to measure biomarkers, inflammation, mediators and biomarkers from healthy volunteers and participants with airways disease at stable state and during acute exacerbation.
IRAS ID
234581
Contact name
Ian Pavord
Contact email
Sponsor organisation
University of Oxford
Duration of Study in the UK
5 years, 0 months, 1 days
Research summary
Airways diseases include asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis and nasal polyps. They are common and are responsible for a large amount of morbidity, mortality and healthcare utilisation and spending.
Current guidelines and treatments for airways diseases generalise treatments for large groups of patents. It is increasingly clear that this approach is no longer fit for purpose as airways diseases are much more diverse than previously thought, requiring new classification and treatment approaches.
This study will look in detail at lung function, lung physiology, and inflammation (in blood, breath, sputum, airway (bronchial) samples and urine) in disease at stable state and at the start and during treatment for an exacerbation (asthma or COPD attack), or in response to other treatment changes. It is hoped that this study will add to the mechanistic understanding of underlying disease processes with a view to identifying biomarkers, distinct patterns of disease and potential treatment opportunities.
REC name
South Central - Oxford B Research Ethics Committee
REC reference
18/SC/0361
Date of REC Opinion
23 Aug 2018
REC opinion
Further Information Favourable Opinion